

Periorbital basal cell carcinoma - a disease with a Janus Face

Basal cell carcinoma (BCC) is the most common cancer type worldwide, with increasing incidence due to a higher ultraviolet (UV) light exposure. The face, especially the periorbital region, is offended by sun exposure and, therefore, is most often the determinate human body region to develop BCCs. Most BCCs are treated straightforwardly and can be cured by excisional surgery. However, some BCCs are challenging to handle, and treatment options have to be adjusted to these situations. In our special series "Diagnosis and Treatment of Periorbital Basal Cell Carcinoma", we take care of this topic within six articles and emphasize the diagnostic and therapeutic options for this cancer around the eye to help the audience improve the best care of periorbital BCCs. Specifically focus of this special series is to address the specific situation of the ocular adnexa with its function to protect the eye and facilitate the tear draining system. Also, the strategies to cure BCCs aim to spare the eyeball and its vision-giving structures like the optic nerve and others.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Frontiers of Oral and Maxillofacial Medicine for the series "Diagnosis and Treatment of Periorbital Basal Cell Carcinoma". The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://fomm.amegroups. com/article/view/10.21037/fomm-22-18/coif). VK, JY and LMH served as the unpaid Guest Editors of the series. LMH serves as an unpaid editorial board member of *Frontiers of Oral and Maxillofacial Medicine* from September 2020 to August 2022. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.



Ludwig M. Heindl



Juan Ye



Vinodh Kakkassery

Frontiers of Oral and Maxillofacial Medicine, 2023

Ludwig M. Heindl^{1,2}

¹Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; ²Center for Integrated Oncology (CIO) Aachen-Bonn-Cologne-Duesseldorf, Cologne, Germany. (Email: Ludwig.heindl@uk-koeln.de) Juan Ye³

³Eye Center; Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. (Email: yejuan@zju.edu.cn) Vinodh Kakkassery⁴

⁴Department of Ophthalmology, University of Lübeck, Lübeck, Germany. (Email: vinodh.kakkassery@uni-luebeck.de) Received: 05 May 2022; Accepted: 23 May 2022; Published online: 18 June 2022.

doi: 10.21037/fomm-22-18

View this article at: http://dx.doi.org/10.21037/fomm-22-18

doi: 10.21037/fomm-22-18 **Cite this article as:** Heindl LM, Ye J, Kakkassery V. Periorbital basal cell carcinoma—a disease with a Janus Face. Front Oral Maxillofac Med 2023;5:11.